Purpose: The aim of this study was to evaluate the efficacy and safety in ocular hypertensive
or open-angle glaucoma patients changed to a latanoprost/timolol fixed combination
(LTFC) from previous therapy. Methods: We employed a retrospective, multicenter,
active-controlled study evaluating patients who had a previous therapy substituted with
LTFC and had a 3-month follow-up. Results: In the 168 patients included in the trial,
LTFC reduced the intraocular pressure (IOP) after switching from previous therapies: timolol
(22.8 ± 3.5 to 19.0 ± 3.9 mmHg, N = 49, p < 0.001), latanoprost (21.2 ± 3.8 to
18.3 ± 2.5 mmHg, N = 54, p < 0.001), and a dorzolamide/timolol fixed combination
(20.9 ± 2.4 to 20.0 ± 2.7 mmHg, N = 32, p = 0.03). In switching from a latanoprost and
timolol unfixed combination, the pressure changed from 18.3 ± 3.8 to 18.9 ± 3.0 mmHg
(N = 33, p = 0.38). LTFC was persistent in 131 (78%) patients within the 3-month treatment
period. The most common adverse event with LTFC was conjunctival hyperemia,
which occurred in patients not previously treated with latanoprost therapy (N = 16, 10%).
Conclusions: LTFC generally provides reduced IOP and limited side effects when substituted
for other common glaucoma therapies, while providing similar pressure when
switched from its own individual components.
